DrugPatentWatch Database Preview
ANGIOMAX Drug Profile
Which patents cover Angiomax, and when can generic versions of Angiomax launch?
Angiomax is a drug marketed by Sandoz Inc and Maia Pharms Inc and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.
The generic ingredient in ANGIOMAX is bivalirudin. There are fourteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the bivalirudin profile page.
Summary for ANGIOMAX
Recent Clinical Trials for ANGIOMAX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Pacific University | Phase 4 |
| Legacy Health System | Phase 4 |
| Qian Gong | Phase 2 |
Recent Litigation for ANGIOMAX
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Medicines Company v. Hospira, Inc. | 2014-05-13 |
| The Medicines Company v. Hospira, Inc. | 2014-05-13 |
| The Medicines Company v. Exela Pharma Sciences, LLC | 2014-04-25 |
Pharmacology for ANGIOMAX
| Drug Class | Anti-coagulant Direct Thrombin Inhibitor |
| Mechanism of Action | Thrombin Inhibitors |
Synonyms for ANGIOMAX
| (R,R)-2,6-Bis(4,5-dihydro-4-phenyl-2-oxazolyl)pyridine; (R,R)-2,6-Bis(4-phenyl-2-oxazolinyl)pyridine; (+)-2,6-Bis[(4R)-4-phenyl-2-oxazolin-2-yl]pyridine |
| 1191386-55-6 |
| 128270-60-0 |
| 270B600 |
| 70B600 |
| AKOS015994644 |
| AN-7543 |
| Angiox |
| BC657176 |
| BG 8967 |
| BG-8967 |
| BG8967 |
| Bivalirudin |
| Bivalirudin [USAN:BAN:INN] |
| Bivalirudin [USAN:INN:BAN] |
| Bivalirudin Trifluoacetate |
| Bivalirudin Trifluoroacetate |
| Bivalirudin;0.9% Sodium Chloride |
| bivalirudina |
| bivalirudine |
| bivalirudinum |
| C98H138N24O33 |
| C9H11NO.C2H6.CH4 |
| CHEBI:59173 |
| CHEMBL2103749 |
| DB00006 |
| EBD32115 |
| GTPL6470 |
| Hirulog |
| Hirulog-1 |
| HS-2004 |
| J-005587 |
| KS-00002WUN |
| LS-172701 |
| MolPort-006-167-455 |
| Phe-Pro-Arg-Pro-(Gly)4 desulfato-Tyr63'-hirugen |
| Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu |
| Phe-Pro-Arg-Pro-(Gly)4-desulfohirudin-(53-64) |
| SCHEMBL25739 |
| TN9BEX005G |
| UNII-TN9BEX005G |
US Patents and Regulatory Information for ANGIOMAX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz Inc | ANGIOMAX | bivalirudin | INJECTABLE;INTRAVENOUS | 020873-001 | Dec 15, 2000 | AP | RX | Yes | Yes | See Pricing | See Pricing | Y | See Pricing | ||
| Sandoz Inc | ANGIOMAX | bivalirudin | INJECTABLE;INTRAVENOUS | 020873-001 | Dec 15, 2000 | AP | RX | Yes | Yes | See Pricing | See Pricing | Y | See Pricing | ||
| Maia Pharms Inc | ANGIOMAX RTU | bivalirudin | SOLUTION;INTRAVENOUS | 211215-001 | Jul 25, 2019 | RX | Yes | Yes | See Pricing | See Pricing | See Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ANGIOMAX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sandoz Inc | ANGIOMAX | bivalirudin | INJECTABLE;INTRAVENOUS | 020873-001 | Dec 15, 2000 | See Pricing | See Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ANGIOMAX
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | For Injection | 250 mg/vial | ➤ Subscribe | See Pricing |
